Hanmi Pharm said that its combination antihypertensive drug, Amosartan Tab, has recorded cumulative sales of 1.05 trillion won ($786.2 million) as of December last year. The record was achieved more than 14 years after its launch, with sales averaging 75 billion won per year.

Amosartan is a drug that combines the calcium channel blocker (CCB)-based amlodipine camsylate and the angiotensin receptor blocker (ARB)-based losartan potassium.

In 2009, Amosartan surpassed 10 billion won in sales in the first six months of its launch, and over the next 14 years, it grew at an average annual rate of 15 percent, reaching 89.2 billion won in sales in 2023.

Hanmi Pharm has continued its sales growth by adding other components to Amosartan for the development of the Amosartan Family product line.

In 2017, it launched Amosartan Plus, a three-drug combo that adds chlorthalidone to Amosartan, and Amosartan Q, a three-drug combo that combines a dyslipidemia drug (rosuvastatin) and Amosartan.

In 2021, the company launched Amosartan XQ, a four-drug combo that adds a dyslipidemia drug (ezetimibe) to Amosartan Q.

The cumulative sales of the Amosartan Family have reached 1.27 trillion won, representing last year's sales of 89.2 billion won for Amosartan, 30.9 billion won for Amosartan Plus, 11.3 billion won for Amosartan Q and 10.5 billion won for Amosartan XQ.

These achievements were based on clinical evidence that proved Amosartan Family's efficacy and safety in various types of patients.

Hanmi Pharm has been publishing an average of one clinical research paper per year based on the Amosartan family in Science Citation Index (SCI)-ranked international journals. So far, 17 clinical research papers have been published in international journals with SCI and SCI-Expanded rankings, providing a solid foundation for evidence-based marketing activities for Amosartan family.

The phase 4 study of the Amosartan Family was a 10-year study of 15,538 patients with hypertension and was published in 2021 in The Journal of Clinical Hypertension titled “Clinical effectiveness and safety of amlodipine/losartan-based single-pill combination therapy in patients with hypertension: Findings from real-world, multicenter observational databases.”

"Amosartan, which was first launched in 2009, is the driving force behind Hanmi Pharm's progress toward new drug development," said a Hanmi Pharm official. "We will continue to develop high-quality therapeutics that are trusted by healthcare providers and patients and provide optimal treatment options."